Latisse Faces Patent Challenge
The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version. (Source: WSJ.com: Health)
More here:
Latisse Faces Patent Challenge
Latisse Faces Patent Challenge
The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version.
Read the original post:
Latisse Faces Patent Challenge
Latisse Faces Patent Challenge
The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version.
See the original post:
Latisse Faces Patent Challenge
FDA: Allergan’s Web Site Is Misleading
The FDA said the Web site of Allergan’s Latisse is misleading because it suggests the company’s eyelash thickener is more safe than proven.
Go here to read the rest:
FDA: Allergan’s Web Site Is Misleading
Allergan Eyelash Enhancer Approved
Allergan received FDA approval to market Latisse, a beauty treatment that increases the length, thickness and darkness of eyelashes by using a drug the company developed to treat glaucoma.
See more here:
Allergan Eyelash Enhancer Approved
